ImpriMed

Pioneering AI-driven Precision Medicine

About the Company

Uses high-throughput biological testing and AI to predict which chemotherapy drugs will work best for specific cancer patients

Industry Sector

BioTech

Tech Stack

Machine Learning Flow Cytometry Personalized Medicine AI

Product

A diagnostic report for veterinarians that ranks the effectiveness of different drug options based on the patient's live cancer cells.

View Product

Startup Details

Investment Stage Series A
Cumulative Investment $10M - $50M
Activity Region North America